Rituximab (Rituxan)

References

1. 1.↵
   1. Avivi I,
   2. Robinson S,
   3. Goldstone A

   . Clinical use of rituximab in haematological malignancies. Br J Cancer 2003;89:1389–94

   CrossRefPubMedWeb of Science
2. 2.↵
   1. McLaughlin P,
   2. Grillo-Lopez AJ,
   3. Link BK,
   4. et al

   . Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four dose treatment program. J Clin Oncol 1998;16:2825–33

   Abstract
3. 3.↵
   1. Marcus R,
   2. Imrie K,
   3. Belch A,
   4. et al

   . CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417–23. Epub 2004 Oct 19

   Abstract/FREE Full Text
4. 4.↵
   1. Coiffier B,
   2. Lepage E,
   3. Briere J,
   4. et al

   . CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–42

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Edwards JC,
   2. Szczepanski L,
   3. Szechinski J,
   4. et al

   . Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572–81

   CrossRefPubMedWeb of Science
6. 6.↵
   1. Reff ME,
   2. Carner K,
   3. Chambers KS,
   4. et al

   . Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435–45

   Abstract/FREE Full Text
7. 7.↵
   1. Maloney DG,
   2. Liles TM,
   3. Czerwinski DK,
   4. et al

   . Phase I clinical trial using escalating single dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994;84:2457–66

   Abstract/FREE Full Text
8. 8.↵
   1. Pesocovitz MD

   . Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am J Transplant 2006;6:859–66

   CrossRefPubMedWeb of Science
9. 9.↵
   1. Ng CM,
   2. Bruno R,
   3. Combs D,
   4. et al

   . Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis during a phase II clinical trial. J Clin Pharmacol 2005;45:792–801

   CrossRefPubMedWeb of Science
10. 10.↵
    1. Adeli MM,
    2. Eichner B,
    3. Thornburg C,
    4. et al

    . Persistent antibody depletion after rituximab in three children with autoimmune cytopenias. Pediatr Hematol Oncol 2009;26:566–72

    CrossRefPubMed
11. 11.↵
    1. Quartier P,
    2. Brethon B,
    3. Philippet P,
    4. et al

    . A treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 2001;358:1511–13

    CrossRefPubMedWeb of Science
12. 12.↵
    Rituxan [package insert]. South San Francisco, California:Biogen-IDEC/Genentech; 2008
13. 13.↵
    1. Carson K,
    2. Focosi D,
    3. Major EO,
    4. et al

    . Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) project. Lancet Oncol 2009;10:816–24

    CrossRefPubMedWeb of Science
14. 14.↵
    1. Shelton E,
    2. Yong M,
    3. Cohney S

    . Late onset pneumocystis pneumonia in patients receiving rituximab for humoral renal transplant rejection. Nephrology 2009;14:696–99

    CrossRefPubMed
15. 15.↵
    1. Goldberg SL,
    2. Pecora AL,
    3. Alter RS,
    4. et al

    . Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood 2002;99:1486–88

    Abstract/FREE Full Text